In-Silico Modelling of Phenotypic Switching in Tumours: Investigating Potentials for Non-invasive Therapies

We developed an in-silico model of cancer growth to investigate the extent to which metabolic switching occurs in tumour masses. Cancer therapies based on glycoconjugation, the linking of a drug to glucose or another sugar, allow improved selectivity and targeting, thus reducing harmful side effects. This mechanism exploits the over-expression of glucose membrane transporters, a phenotypic alterat...